Description
Background:
Vonlerolizumab, also known as IMC-20D7S, is an investigational monoclonal antibody that targets the protein called TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT is a receptor found on certain immune cells, including T cells and natural killer (NK) cells, and it plays a role in regulating immune responses.
By binding to TIGIT, vonlerolizumab aims to modulate the immune system and potentially enhance anti-tumor immune responses. It is being studied as an immunotherapy for various types of cancer, including solid tumors and hematological malignancies.
Intended Use:
For Estimation of Vonlerolizumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!